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SHORT COMMUNICATION
Decreased tyrosine phosphorylation in tumour cells resistant to FCE
24517 (tallimustine)
M Ciomei, W Pastori, L Capolongo, C Geroni, G Melegaro, G Pennella and M Grandi
Pharmacia, R&D/B.A. Pharmaceuticals, Experimental Oncology Department, Via Giovanni XXIII no. 23, 20014 Nerviano MI -
Itab,.
Summary Resistance to FCE 24517 is not related to the emergence of any of the most frequently observed
phenotypes. We have found that two resistant cell lines (L1210/24517 murine leukaemia and LoVo/24517
human colon adenocarcinoma) present congenital modifications in tyrosyl phosphatase and kinase activities.
Moreover, the cytotoxic activity of FCE 24517 is increased in combination with a tyrosine phosphatase
inhibitor and decreased in combination with protein kinase inhibitors, this being in agreement with the
hypothesis that the activity of this drug is strictly dependent on the presence of tyrosine phosphorylated
protein(s).
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FCE 24517 (tallimustine), a benzoyl mustard derivative of
distamycin A, is a new anti-tumour agent which has shown a
remarkable preclinical anti-tumour activity (Barbieri et al.,
1988; Arcamone et al., 1989) and is now in phase II clinical
trials (Abigerges et al., 1993; Hageboutros et al., 1994; Sessa
et al., 1994).
A murine leukaemia L1210 line (L1210/24517) and a
human colon adenocarcinoma line (LoVo/24517) resistant to
FCE 24517 have been recently described (Capolongo et al.,
1993; Geroni et al., 1993). These cell lines maintain the same
growth features and biological behaviour as the parental line
and are specifically resistant in vitro and in vivo to the
selecting agent and other distamycin A derivatives bearing
different alkylating moieties, such as nitrogen mustard,
epoxycarbonyl and halogenoacriloyl group on the N-terminal
position of distamycin A (D'Alessio et al., 1994). As regards
other cytotoxic agents, the L1210/24517 subline does not
present the multidrug resistance (MDR) phenotype and is
fully sensitive to anti tumour compounds involved in the
MDR mechanism and to alkylating agents (e.g. cisplatin)
(Geroni et al., 1993). Moreover, it is partially cross-resistant
to melphalan, this resistance being accounted for by higher
glutathione and glutathione-S-transferase intracellular levels,
which however do not influence the resistance to FCE 24517
(Geroni et al., 1993; Tagliabue et al., 1993). The LoVo/24517
subline is partially different, because it is marginally resistant
to doxorubicin, VP-16 and vinblastine, because the mdr-I
mRNA expression is elevated 2-fold. In this case the resis-
tance selected by FCE 24517 is partially mediated through
p170 overexpression, but the main mechanism still remains to
be established.
Further possible explanations for drug resistance were
examined, such as, for example, the presence of a more
efficient repair of the DNA damage caused by FCE 24517.
This compound is able to alkylate adenine-N3 located in
highly specific DNA sequences (Broggini et al., 1991) and
therefore an increase in adenine N3 glycosylases could pro-
tect the cells; however, the significant cross-resistance to the
parent compound distamycin A, which is not an alkylating
agent, is completely in contrast with this hypothesis. We now
report that a congenital modification in the phosphorylation
balance is present in the resistant sublines. The importance of
a well-regulated balance between phosphorylation and
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dephosphorylation for the mode of action of FCE 24517 is
strengthened by the increased cytotoxicity of FCE 24517
observed in combination with a tyr-phosphatase inhibitor in
both sensitive and resistant cells.
Materials and methods
Chemicals
FCE 24517 was synthesised in the Chemical Department of
Pharmacia, Farmitalia Carlo Erba, Milan, Italy. The drug
was dissolved in sterile water immediately before use and the
concentration was checked spectrophotometrically following
dilution of aliquots of the drug solution in ethanol: Amax =
314 nm, E 1% = 744.09. Herbimycin and staurosporine were
obtained from Calbiochem (San Diego, CA, USA); genistein,
quercetin and sodium orthovanadate were from Sigma (St.
Louis, MO, USA).
Sodium orthovanadate (Na-V) was dissolved in water; her-
bimycin, staurosporine, genistein and quercetin were dis-
solved in DMSO (maximum concentration in the assays 1%,
which has no effect on cell proliferation).
Cell cultures
L1210 and L1210/24517 murine leukaemia cell lines were
grown in vitro as a stationary suspension culture in RPMI-
1640 medium (Gibco, Grand Island, NY, USA) supp-
lemented with 10% fetal calf serum (FCS) (Flow, Irvine,
UK), 2mM L-glutamine (Gibco Europe, Glasgow, UK),
10 M ,-mercaptoethanol, 100 Unit ml-' penicillin and
100jig ml-' streptomycin.
LoVo and LoVo/24517 human colon adenocarcinoma cell
lines were maintained in Ham's F12 medium (Gibco, Grand
Island, NY, USA) supplemented with 10% FCS, 1%
vitamins (vitamins BME solution, 100 x, Gibco) and 2 mM
L-glutamine.
Drug sensitivity assays
To determine the antiproliferative effect of the combination
of Na-V or protein kinase inhibitors with FCE 24517, L1210
and L1210/24517, exponentially growing cells were seeded
(1 x I05 cells ml-') in T25 flasks (Costar, Cambridge, MA,
USA) in the presence or absence of Na-V or protein kinase
inhibitors. After 48 h incubation cells were readjusted to theconcentration of 1 x I05 cellsml-', reseeded in test tubes
(1 ml per tube) and treated for 1 h with different concentra-
tions of FCE 24517 in the presence of Na-V or protein
kinase inhibitors. At the end of the treatment, the cells were
washed and incubated in drug-free medium for 48 h; inhibi-
tion of cell growth was evaluated by counting surviving cells
in a ZBI Coulter Counter (Hialeah, FL, USA). LoVo and
LoVo/24517 cells were seeded in 35 mm plastic dishes at a
concentration of 600 cells per dish; after 24 h cells were
treated with Na-V for 48 h. FCE 24517 was added for the
last 4 h, then the medium was replaced with fresh medium
and colonies were counted after 8-10 days using an optical
microscope.
The 50% inhibitory concentration (IC50) was calculated on
the derived concentration-response curves. For each drug
concentration duplicate cultures were used.
Antiphosphotyrosine blots
For total protein extracts, cells in exponential growth were
washed twice with phosphate-buffered saline (PBS) and
treated with 1 mm Na-V for 15 min (LoVo cells) or 60 min
(LI210 cells) in serum-free medium. After exposure, the
pelleted cells were solubilised in boiling Laemmli buffer. The
cell lysates were immediately boiled for 5 min and sonicated.
In each sample of total protein extracts the protein content
was estimated by the Pierce protein assay (bicinchoninic acid
assay) and adjusted to an equivalent concentration in order
to load 3001.g of protein per lane for separation by
SDS-PAGE on a 10% acrylamide slab gel.
The SDS-PAGE separated proteins were transferred
electrophoretically to a nitrocellulose sheet that was soaked
as described (Toedin et al., 1979). The nitrocellulose sheets
were then incubated 1 h at room temperature in the presence
of 2tig ml-' of antiphosphotyrosine antibody monoclonal
IgG2bk (UBI, Lake Placid, NY, USA). After washing, blots
were incubated with horseradish peroxidase-linked whole
antibody anti-mouse Ig at room temperature for 1 h. Detec-
tion using the ECL reagents (Amersham, UK) was accomp-
lished by mixing them in a ratio of 1: 1 and applying to the
nitrocellulose surface for 1 min. Excess reagent was drained
off and the membrane exposed for 30 s to Hyperfilm-ECL.
The molecular weight of the phosphoproteins was est-
imated relative to the electrophoretic mobility of co-
transferred, prestained protein standards (Amersham, UK).
The total optical density of the different lanes was
measured using an Imaging Analyser (Vidas Plus, Zeiss),
program Ibas 20, Kontron Electronik.
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to Butler et al., 1989). After 30 min at 30°C, the reaction was
stopped by adding 250Isg of BSA as carrier protein and
100flI of 20% TCA and proteins were precipitated in liquid
nitrogen. The samples were then centrifuged in an Eppendorf
centrifuge for 10 min and the 32p content of the pellets
resuspended in 0.1 M Tris pH 8.0 was determined.
Results
Studies on tyrosine phosphorylatedproteins
No changes in the total protein content of the FCE 24517
resistant subclones in comparison with the protein content of
the parental cell lines, LoVo and L1210, were seen after
SDS-PAGE and Coomassie staining (not shown). On the
contrary, Figure 1 shows the difference observed after
immunodetection of the same blotted gels with an antiphos-
photyrosine monoclonal antibody: a general reduced phos-
phorylation in tyrosine was present in the LoVo/24517 pro-
teins (lane 4 in comparison with lane 1) together with a
reduced sensitivity of the resistant line (lanes 5 and 6 in
comparison with lanes 2 and 3) to a 15 min treatment with a
tyrosine phosphatase inhibitor, sodium orthovanadate
(Tonks et al., 1988). Figure 2 shows the quantitative den-
sitometric evaluation of three repeated experiments on LoVo
and LoVo/24517 cells and of similar experiments on L1210
and L1210/24517 cells: also in the case of L1210 cells, the
proteins of the resistant line presented a reduced phosph-
orylation in tyrosine.
Studies onphosphotyrosyl-specific phosphatase activity
The general picture of reduced tyr-phosphorylation seen in
total protein extracts of both resistant sublines was in agree-
ment with the hypothesis of a modification either in the
tyr-phosphatase activity or in the tyr-kinase activity of the
resistant sublines. The total PTPase activity in membrane
extracts of both sensitive and resistant subclones was
evaluated as the ability to dephosphorylate 32P-myelin basic
protein phosphorylated by abl oncogene product.
As shown in Figure 3 the phosphotyrosyl-specific phos-
phatase activity is increased in the protein membrane extract
of L1210/24517 cells in comparison with the activity of the
membrane extract of the parental L1210 cell line, whereas no
difference was observed with LoVo and LoVo/24517 mem-
brane extracts.
Phosphotyrosyl-specific protein phosphatase (PTPase) assay
A standard 100;lI reaction contained 100 000 c.p.m. 32P-
labelled substrate 32P-Tyr-myelin basic protein, labelled at its
tyrosine residue using [7_-32P]ATP and v-abl tyrosine kinase as
described by Streuli et al., 1990) in buffer A: 50 mM Hepes,
5 mM EDTA, 10 mM DTT, 50mM sodium chloride, 50fig ml-' bovine serum albumin (BSA) pH 7.0.
The reaction was initiated by the addition of the appropri-
ate dilution of membrane protein samples (extracted accord-
ing to Butler et al., 1989). After different times at 30°C, the
reaction was stopped by adding 500 sg of BSA as carrier
protein and 200 1l of 20% trichloroacetic acid (TCA) and
proteins were precipitated in liquid nitrogen. The samples
were then centrifuged in an Eppendorf centrifuge for 10 min
and the 32p content of the supernatant was determined.
Tyrosine kinase assay
A standard 50 p1 reaction contained 0.1IlI [?-32P]ATP
(6000 Ci mmol'l, 10 mCiml1-', NEN DUPONT), 10jigml1'
myelin basic protein, 3 mM sodium orthovanadate, 50 l4M
ATP in buffer B: 25 mM Tris, 0.1 mM DTT, 1OmM mag-
nesium chloride pH 8.0.
The reaction was initiated by addition of the appropriate
dilution of membrane protein samples (extracted according
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Figure 1 Tyrosine-phosphorylated proteins in total extracts of
LoVo and LoVo/24517 cells: treatment with sodium ortho-
vanadate. Cell treatments were performed with 0.1 and 1 mM
Na-V for 15 min. Total proteins, extracted in Laemmli sample
buffer, were separated by SDS-PAGE and transferred to a nit-
rocellulose sheet. The blot was probed with a monoclonal
antiphosphotyrosine antibody. This is one representative experi-
ment of three. Lanes 1-3: LoVo cells (1, control; 2, 0.1 mM
Na-V; 3, 1 mM Na-V); lanes 4-6: LoVo/24517 cells (4, control;
5, 0.1 mM Na-V; 6, 1 mM Na-V). Standard proteins: myosin (H
chain) 200 (mol. wt in kDa), phosphorylase B 97.4; bovine serum
albumin 69.
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On the contrary, a decreased tyrosine kinase activity was
observed in the LoVo/24517 extract in comparison with
LoVo extract, whereas no change was observed in the same
membrane extracts of L1210 cell lines (Figure 4). The addi-
tion of FCE 24517 in these assays had no effect (not shown).
Effect ofsodium orthovanadate treatment on FCE 24517
cytotoxicity
With the aim of confirming that the regulation of tyrosine
phosphorylation was related to resistance to FCE 24517, we
tested if the treatment with an inhibitor of the tyr-
phosphatase activity could affect the sensitivity of both sen-
sitive and resistant cell lines to FCE 24517.
As shown in Table I, a 48 h pretreatment with non-toxic
doses of sodium orthovanadate (2.7, 5.4 and 10.8 gM for
L1210 lines and 12.5 and 17 LM for LoVo lines) was
observed to increase the cytotoxic activity of FCE 24517 in a
dose-dependent way.
Effect ofprotein kinase inhibitors treatment on FCE 24517
cytotoxicity
The same treatment reported for sodium orthovanadate has
been repeated with different classes of protein kinase
inhibitors. On LoVo cell lines, no significant modification of
FCE 24517 cytotoxicity has been observed in combination
with the tyr-kinase inhibitor genistein and the protein kinase
inhibitor staurosporine. The only effect was observed with
the tyr-kinase inhibitor quercetin: the ID50 value of FCE
24517 in combination with 6.6 nM quercetin was increased by
49% and 41% for LoVo and LoVo/24517 respectively.
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Figure 2 Tyrosine - phosphorylated proteins in total extracts of
LoVo, LoVo/24517, L1210 and L1210/24517 cells. Evaluation of
the total optical density of the protein lanes by imaging analysis.
Open columns, untreated cells, hatched columns, cells treated
with 1 mM Na-V (5 min for LoVo cells, 240 min for L1210
cells).
Table 1 Cytotoxicity of FCE 24517 in combination with non-toxic
doses of sodium orthovanadate (Na-V)
IC50 (ngml-')
Treatment LoVo a LoVoI24517a
FCE 24517 330 ± 25 8300 ± 650
FCE 24517 + Na-V 12.5 ttMb 104 ± 8 5200
FCE 24517 + NA-V 17.0jMb 41 3150 ± 275
LJ2JOc L1210/24517C
FCE 24517 169 26 3368 127
FCE 24517 + Na-V 2.7jLmb 126 ± 13 2704 ± 350
FCE 24517 + Na-V 5.4limb 104 ± 12 2668 _ 245
FCE 24517 + Na-V 10.8,Mb 97 11 1091 215
aForty-eight hours treatment with Na-V. FCE 24517 was added for
the last 4 h. Colony number was counted after 8 days. bAll the Na-Vdoses used in combination with FCE 24517 are non-toxic
(survival > 75%).
cForty-eight hours treatment with Na-V. FCE 24517 was added for the
last hour. Cell number was evaluated after 48 h.
Higher doses ofquercetin were toxic. On L1210 cell lines, no
influence on the cytotoxic activity of FCE 24517 was
observed with genistein and herbimycin.
Table II reports the results obtained after pretreatment
with non-toxic doses of quercetin and staurosporine. The
cytotoxic activity of FCE 24517 was decreased in a dose-
dependent way. This effect was more evident on the resistant
L1210/24517 cells.
Discussion
Results presented in this paper show that both sublines resis-
tant to the antineoplastic agent FCE 24517 present a con-
genital modification in the tyrosyl-specific phosphatase and
kinase balance: L1210/24517 cells present an increase in the
phosphatase activity whereas LoVo/24517 cells present a
decrease in the kinase activity. This modification is related to
a decrease in tyrosine phosphorylation levels of LoVo/24517
and L1210/24517 protein extracts. Moreover, by using a
Time (min)
Figure 3 Phosphotyrosyl-specific phosphatase activity in mem-
brane 'extracts of LoVo, LoVo/24517, L1210 and L1210/24517
cells. Aliquots of lOng of membrane proteins (LoVo V; LoVo/
24517 V; L1210 0; L1210/24517 0) were added to 32P-Tyr-
myelin basic protein and incubated at 30C. 32P release was
determined at different times. Values represent the average of
three determinations. Bars, s.e. (when bars are not shown they
are smaller than the symbol).
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Figure 4 Tyrosine kinase activity in membrane extracts of
LoVo, LoVo/24517, L1210 and L1210/24517 cells. Aliquots of
membrane proteins (LoVo V; LoVo/24517 V; L1210 0; L1210/
24517 0) were added to 32P-ATP and myelin basic protein in the
presence of 3mM sodium orthovanadate at 30°C. 32p incor-
porated in the protein was determined after 30 min. Values repre-
sent the average of three determinations. Bars, s.e. (when bars are
not shown they are smaller than the symbol).
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Table II Cytotoxicity of FCE 24517 in combination with non-toxic doses of
staurosporine and quercetin
Ic50 (ngml')
Treatment LJ21Jb L1210/24517b
FCE 24517 209 18 2800 256
FCE 24517 + staurosporine 1.5 nMa 463 + 104 7455 + 61
FCE 24517 + staurosporine 3.0 nMa 481 ± 102 8840 ± 305
FCE 24517 + quercetin 5000 nMa 279 3703 ± 48
FCE 24517 + quercetin 10 000 nMa 334 7858 ± 303
aAll the doses ofprotein kinase inhibitors used in combination with FCE 24517 are
non-toxic (survival >75%).
bForty-eight hours treatment with protein kinaseinhibitors. FCE24517 wasaddedfor
the last hour. Cell number was evaluated after 48 h.
phosphatase inhibitor (sodium orthovanadate) in combina-
tion with FCE 24517 it is possible to increase the cytotoxic
effect of FCE 24517. This effect is evident not only on the
resistant cells but also on the sensitive cells: it is not a
reversion of the resistance phenotype, but a demonstration of
the importance of tyrosine phosphorylation for the mode of
action of FCE 24517.
In agreement with this hypothesis, an opposite effect has
been observed in combination with two protein kinase
inhibitors (quercetin and staurosporine) on L1210 and
L1210/24517 cells. This effect was less evident on LoVo cells:
a combination of more than one protein kinase inhibitor
could be necessary on this model.
The mechanism of resistance selected by treatment with
FCE 24517 in L1210 leukaemia and LoVo colon adenocar-
cinoma cells has not been found correlated to any of the
changes frequently involved in the drug resistance.
One ofthe mechanisms most frequently involved in the cell
resistance to cytotoxic drugs is the decrease of drug
accumulation, either by decreasing its uptake or by increas-
ing the efflux. In fact many tumour cell lines become resistant
to structurally and functionally unrelated compounds with
the overexpression of the mdr-J gene, coding for a P-gp 170
that acts as a drug efflux pump (Endicott and Ling, 1989;
Gottesman, 1993). L1210/24517 cells are MDRl-negative
(Geroni et al., 1993) and LoVo/24517 cells present only a
2-fold increase in mdr-J gene (Capolongo et al., 1993).
More similar to the L1210/24517 and LoVo/24517 cell
lines is a nitrogen mustard-resistant Walker 256 rat breast
carcinoma cell line which presents changes in the phos'
phorylation balance. However in this case a different enzyme
is involved: a decreased specific activity of a cAMP-
dependent protein kinase influenced a different nuclear mat-
rix protein phosphorylation profile (Moy and Tew, 1986).
Moreover, a decreased phosphorylation of a p66 protein
has been described in the membrane of a L1210 cell line
resistant to cisplatin (Xuan et al., 1994), which also exhibited
a decreased methotrexate uptake.
From the data presented here a balance between tyrosine
phosphorylation and dephosphorylation activity seems to be
important for the activity of FCE 24517. We have
hypothesised that the protein(s) involved in the mode of
action of this drug need to be phosphorylated to work.
Experiments to identify the protein(s) involved in the mode
of action and, consequently, in the resistance mechanism of
FCE 24517 are in progress.
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